Aytu Biopharma Inc (AYTU)

$2.8

-0.02

(-0.71%)

Market is closed - opens 7 PM, 17 Jul 2024

Performance

  • $2.76
    $2.86
    $2.80
    downward going graph

    1.43%

    Downside

    Day's Volatility :3.5%

    Upside

    2.1%

    downward going graph
  • $1.52
    $3.50
    $2.80
    downward going graph

    45.71%

    Downside

    52 Weeks Volatility :56.57%

    Upside

    20.0%

    downward going graph

Returns

PeriodAytu Biopharma IncIndex (Russel 2000)
3 Months
-2.55%
0.0%
6 Months
12.0%
0.0%
1 Year
54.7%
0.0%
3 Years
-96.64%
-18.2%

Highlights

Market Capitalization
16.8M
Book Value
$5.53
Earnings Per Share (EPS)
-2.44
PEG Ratio
0.0
Wall Street Target Price
8.0
Profit Margin
-14.6%
Operating Margin TTM
-12.34%
Return On Assets TTM
0.66%
Return On Equity TTM
-38.18%
Revenue TTM
93.8M
Revenue Per Share TTM
18.21
Quarterly Revenue Growth YOY
-20.9%
Gross Profit TTM
66.6M
EBITDA
9.9M
Diluted Eps TTM
-2.44
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.49
EPS Estimate Next Year
0.65
EPS Estimate Current Quarter
-0.64
EPS Estimate Next Quarter
-0.06

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Aytu Biopharma Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 185.71%

Current $2.80
Target $8.00

Company Financials

FY18Y/Y Change
Revenue
3.7M
↑ 13.61%
Net Income
-10.2M
↓ 54.74%
Net Profit Margin
-278.36%
↑ 420.31%
FY19Y/Y Change
Revenue
7.3M
↑ 100.01%
Net Income
-47.2M
↑ 362.97%
Net Profit Margin
-644.33%
↓ 365.97%
FY20Y/Y Change
Revenue
27.6M
↑ 277.47%
Net Income
-3.7M
↓ 92.16%
Net Profit Margin
-13.39%
↑ 630.94%
FY21Y/Y Change
Revenue
65.6M
↑ 137.52%
Net Income
-58.3M
↑ 1475.55%
Net Profit Margin
-88.81%
↓ 75.42%
FY22Y/Y Change
Revenue
96.7M
↑ 47.29%
Net Income
-110.2M
↑ 89.01%
Net Profit Margin
-113.97%
↓ 25.16%
FY23Y/Y Change
Revenue
107.4M
↑ 11.1%
Net Income
-17.1M
↓ 84.52%
Net Profit Margin
-15.88%
↑ 98.09%
Q4 FY22Q/Q Change
Revenue
26.3M
↓ 4.98%
Net Income
-10.4M
↑ 145.22%
Net Profit Margin
-39.54%
↓ 24.22%
Q1 FY23Q/Q Change
Revenue
22.7M
↓ 13.49%
Net Income
-5.8M
↓ 43.77%
Net Profit Margin
-25.7%
↑ 13.84%
Q2 FY23Q/Q Change
Revenue
30.7M
↑ 35.19%
Net Income
-2.5M
↓ 57.94%
Net Profit Margin
-7.99%
↑ 17.71%
Q3 FY23Q/Q Change
Revenue
30.7M
↑ 0.0%
Net Income
-2.5M
↑ 0.0%
Net Profit Margin
-7.99%
↑ 0.0%
Q4 FY23Q/Q Change
Revenue
22.9M
↓ 25.37%
Net Income
-220.0K
↓ 91.05%
Net Profit Margin
-0.96%
↑ 7.03%
Q1 FY24Q/Q Change
Revenue
18.0M
↓ 21.54%
Net Income
-2.9M
↑ 1212.27%
Net Profit Margin
-16.05%
↓ 15.09%
FY18Y/Y Change
Total Assets
21.1M
↑ 40.41%
Total Liabilities
7.6M
↓ 30.58%
FY19Y/Y Change
Total Assets
34.7M
↑ 64.87%
Total Liabilities
27.6M
↑ 261.9%
FY20Y/Y Change
Total Assets
152.8M
↑ 340.18%
Total Liabilities
57.8M
↑ 109.24%
FY21Y/Y Change
Total Assets
265.7M
↑ 73.83%
Total Liabilities
128.1M
↑ 121.55%
FY22Y/Y Change
Total Assets
137.6M
↓ 48.2%
Total Liabilities
91.5M
↓ 28.55%
FY23Y/Y Change
Total Assets
136.5M
↓ 0.84%
Total Liabilities
97.1M
↑ 6.09%
Q4 FY22Q/Q Change
Total Assets
141.4M
↓ 5.71%
Total Liabilities
95.6M
↓ 0.49%
Q1 FY23Q/Q Change
Total Assets
147.2M
↑ 4.09%
Total Liabilities
106.3M
↑ 11.17%
Q2 FY23Q/Q Change
Total Assets
136.5M
↓ 7.3%
Total Liabilities
97.1M
↓ 8.65%
Q3 FY23Q/Q Change
Total Assets
136.5M
↑ 0.0%
Total Liabilities
97.1M
↑ 0.0%
Q4 FY23Q/Q Change
Total Assets
131.2M
↓ 3.82%
Total Liabilities
98.4M
↑ 1.33%
Q1 FY24Q/Q Change
Total Assets
128.9M
↓ 1.82%
Total Liabilities
98.1M
↓ 0.32%
FY18Y/Y Change
Operating Cash Flow
-15.9M
↑ 15.26%
Investing Cash Flow
-484.3K
↓ 86.3%
Financing Cash Flow
22.7M
↑ 122.42%
FY19Y/Y Change
Operating Cash Flow
-13.8M
↓ 13.23%
Investing Cash Flow
-1.1M
↑ 119.29%
Financing Cash Flow
19.1M
↓ 15.82%
FY20Y/Y Change
Operating Cash Flow
-28.4M
↑ 105.14%
Investing Cash Flow
-5.7M
↑ 432.57%
Financing Cash Flow
71.1M
↑ 272.57%
FY21Y/Y Change
Operating Cash Flow
-26.0M
↓ 8.49%
Investing Cash Flow
-2.8M
↓ 50.81%
Financing Cash Flow
30.3M
↓ 57.35%
FY22Y/Y Change
Operating Cash Flow
-28.8M
↑ 11.01%
Investing Cash Flow
-3.2M
↑ 16.75%
Financing Cash Flow
1.5M
↓ 94.95%
FY23Y/Y Change
Operating Cash Flow
-5.1M
↓ 82.21%
Investing Cash Flow
-117.0K
↓ 96.4%
Financing Cash Flow
8.9M
↑ 479.8%
Q4 FY22Q/Q Change
Operating Cash Flow
-2.4M
↓ 73.33%
Investing Cash Flow
-5.0K
↓ 111.9%
Financing Cash Flow
-1.9M
↓ 113.76%
Q1 FY23Q/Q Change
Operating Cash Flow
-2.9M
↑ 19.1%
Investing Cash Flow
-155.0K
↑ 3000.0%
Financing Cash Flow
2.6M
↓ 238.5%
Q2 FY23Q/Q Change
Operating Cash Flow
9.4M
↓ 422.26%
Investing Cash Flow
-155.0K
↑ 0.0%
Financing Cash Flow
-5.4M
↓ 309.21%
Q3 FY23Q/Q Change
Operating Cash Flow
9.4M
↑ 0.0%
Investing Cash Flow
-76.0K
↓ 50.97%
Financing Cash Flow
-5.4M
↑ 0.0%

Technicals Summary

Sell

Neutral

Buy

Aytu Biopharma Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aytu Biopharma Inc
Aytu Biopharma Inc
-0.36%
12.0%
54.7%
-96.64%
-99.21%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
8.99%
7.53%
53.59%
57.28%
67.33%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
4.54%
3.31%
4.67%
18.08%
18.08%
Zoetis Inc.
Zoetis Inc.
7.03%
-4.19%
7.13%
-7.54%
60.9%
Viatris Inc.
Viatris Inc.
12.56%
-0.7%
13.69%
-16.32%
-30.35%
Catalent, Inc.
Catalent, Inc.
4.78%
19.08%
24.52%
-47.81%
7.61%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aytu Biopharma Inc
Aytu Biopharma Inc
NA
NA
0.0
-2.49
-0.38
0.01
NA
5.53
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.96
39.96
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.27
29.27
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
34.29
34.29
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aytu Biopharma Inc
Aytu Biopharma Inc
Buy
$16.8M
-99.21%
NA
-14.6%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.8B
67.33%
39.96
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.1B
18.08%
29.27
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$81.2B
60.9%
34.29
27.38%
Viatris Inc.
Viatris Inc.
Hold
$13.2B
-30.35%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.5B
7.61%
211.02
-28.44%

Insights on Aytu Biopharma Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 30.73M → 17.99M (in $), with an average decrease of 23.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -220.0K → -2.88M (in $), with an average decrease of 1212.3% per quarter

  • Vs NBIX

    In the last 3 years, Neurocrine Biosciences Inc. has given 55.2% return, outperforming this stock by 151.9%

Institutional Holdings

  • Nantahala Capital Management, LLC

    19.52%
  • Stonepine Capital Management Llc

    8.49%
  • Renaissance Technologies Corp

    1.28%
  • Geode Capital Management, LLC

    0.62%
  • Vanguard Group Inc

    0.50%
  • BlackRock Inc

    0.41%

Company Information

aytu bioscience is a specialty healthcare company focused on developing and commercializing novel products in the field of urology. aytu is initially concentrating on prostate cancer, male premature ejaculation and male infertility and plans to expand into other urological indications for which there are significant medical needs. the company currently markets prostascint®, an fda-approved radioimaging agent indicated to detect prostate specific membrane antigen (psma) in the assessment and staging of prostate cancer. the company’s most advanced therapeutic is zertane™, an oral therapeutic entering phase 3 clinical studies in the united states as an as needed treatment for premature ejaculation (pe). aytu is also conducting clinical trials with the company’s mioxsys™ system as a novel, point-of-care diagnostic system with the potential to become a standard of care in the diagnosis and management of male infertility.

Organization
Aytu Biopharma Inc
Employees
150
CEO
Mr. Joshua R. Disbrow
Industry
Consumer Services

FAQs